Low-dose docetaxel, estramustine and dexamethasone combination chemotherapy for hormone-refractory prostate cancer

The objective of this study was to evaluate the efficacy and safety of low-dose docetaxel, estramustine and dexamethasone combination chemotherapy in patients with hormone-refractory prostate cancer (HRPC). Sixty-nine patients with HRPC were enrolled. Docetaxel was given at a dose of 25 mg/m(2) on d...

Description complète

Détails bibliographiques

Publié dans:	Hinyokika kiyo. Acta urologica Japonica. - 1962. - 56(2010), 4 vom: 25. Apr., Seite 203-7
Auteur principal:	Kobayashi, Kazuki (Auteur)
Autres auteurs:	Yokonishi, Tetsuhiro, Ito, Yusuke, Matsumoto, Tatsuya, Umemoto, Susumu, Osaka, Kimito, Nakamura, Masafumi, Onuki, Tatsuaki, Komiya, Atsushi, Ohgo, Yoshiharu, Sakai, Naoki, Noguchi, Sumio, Kishi, Hiroichi, Yokomizo, Yumiko, Kawai, Masaki, Okajima, Kazuto, Tajiri, Takehiro, Fujikawa, Atsushi, Ohta, Junichi, Yumura, Yasushi, Moriyama, Masatoshi
Format:	Article
Langue:	Japanese
Publié:	2010
Accès à la collection:	Hinyokika kiyo. Acta urologica Japonica
Sujets:	Journal Article Biomarkers, Tumor Taxoids Docetaxel 15H5577CQD Estramustine 35LT29625A Dexamethasone 7S5I7G3JQL Prostate-Specific Antigen EC 3.4.21.77